WHO ICTRP trial
A prospective, real-world clinical study of albumin-bound paclitaxel combined…
ChiCTR2000039418 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2000039418 |
|---|---|
| Public title | A prospective, real-world clinical study of albumin-bound paclitaxel combined with Sindilizumab in the treatment of non-small cell lung cancer |
| Scientific title | A prospective, real-world clinical study of albumin-bound paclitaxel combined with Sindilizumab in the treatment of non-small cell lung cancer |
| Primary sponsor | The Second People's Hospital of Neijiang |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Observational study |
| Phase | 0 |
| Countries | China |
| Conditions | Non-small cell lung cancer |
| Interventions | case series:Immunotherapy combined with chemotherapy or chemotherapy |
| Registration date | Oct 27, 2020 |
| Target size | case series:400 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: